Glioma News and Research

RSS

Glioma is a cancer of the brain that begins in glial cells (cells that surround and support nerve cells).

GW Pharmaceuticals receives U.S. patent for treating glioma

GW Pharmaceuticals plc, a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Application Serial Number 12/996,124, a patent which covers the use of cannabinoids for treating glioma.

11 Dec 2013

Study finds two distinct subtypes in pediatric diffuse intrinsic pontine gliomas

Children's National researcher, Javad Nazarian, PhD, authored a new study entitled, "Comparative Multidimensional Molecular Analyses of Pediatric Diffuse Intrinsic Pontine Glioma Reveals Distinct Molecular Subtypes." The study found, for the first time, two distinct subtypes in pediatric diffuse intrinsic pontine gliomas.

4 Dec 2013

Researchers use hyperthermia to treat patients with malignant glioma

Malignant glioma is very sensitive to heat. Prof. Yunlong Ge and team from the Second Affiliated Hospital of Harbin Medical University, China used a brain tumor hyperthermia apparatus to treat malignant glioma patients, and achieved good therapeutic efficacy.

3 Dec 2013

CRI researcher receives grant from DIPG to research on pediatric brain tumors

Javad Nazarian, PhD, a researcher with Children's Research Institute (CRI) at Children's National, is the recipient of a $99,979 grant from the DIPG Collaborative for his proposal entitled, "Comparative Proteomic and RNA Sequencing of DIPGs."

27 Nov 2013

Researchers identify new form of treatment for brain tumor

Glioblastoma is one of the most ominous brain tumors. Despite aggressive surgery, radiation and chemotherapy the outcome of this disease is almost always fatal.

26 Nov 2013

Phase 1/2 clinical trial data for VAL-083 in glioblastoma is presented at 18th Annual SNO meeting

DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" and "DelMar Pharma") today announced the presentation of interim data from a Phase 1/2 clinical trial for VAL-083 in recurrent glioblastoma (GBM) at the 4th Quadrennial Meeting of the World Federation of Neuro-Oncology (WFNO) being held in conjunction with the 18th Annual Society for Neuro-Oncology (SNO) meeting in San Francisco.

25 Nov 2013

immatics, Roche enter into cancer vaccine and immunotherapy deal

immatics biotechnologies GmbH and Roche today announced a strategic research and development collaboration covering multiple cancer vaccines and immunotherapeutics.

13 Nov 2013

Study: Hospitals vary in management of children with traumatic brain injury

Hospitals vary in management of children with traumatic brain injury—particularly in monitoring and preventing the harmful effects of increased intracranial pressure (ICP), according to a study in the November issue of Neurosurgery, official journal of the Congress of Neurological Surgeons.

12 Nov 2013

Delmar Pharmaceuticals announces quarterly update, strengthens intellectual property portfolio

As of September 30, 2013, Delmar Pharmaceuticals has cash and equivalents of approximately $5.2 million and its working capital balance is in line with its expectations.

11 Nov 2013

GW Pharmaceuticals starts Phase 1b/2a clinical trial for Recurrent Glioblastoma Multiforme

GW Pharmaceuticals plc a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced today it has commenced a Phase 1b/2a clinical trial for the treatment of Recurrent Glioblastoma Multiforme.

11 Nov 2013

TGen-led study reveals viable target to prevent spread of brain cancer

A cellular pathway interaction known as TWEAK-Fn14, often associated with repair of acute injuries, also is a viable target for drug therapy that could prevent the spread of cancer, especially brain cancer, according to a study led by the Translational Genomics Research Institute.

11 Nov 2013

Investigators find potential new target for treatment of low-grade gliomas

Investigators at Johns Hopkins have found a known genetic pathway to be active in many difficult-to-treat pediatric brain tumors called low-grade gliomas, potentially offering a new target for the treatment of these cancers.

7 Nov 2013

Study suggests neural stem cells have tendency for malignant transformation

Although it is believed that glioma is derived from brain tumor stem cells, the source and molecular signal pathways of these cells are still unclear.

30 Oct 2013

Meta-analysis shows that XRCC1 Arg399Gln polymorphism may be a biomarker of glioma susceptibility

DNA damage is an important mechanism of glioma. X-ray cross-complementing group 1 (XRCC1) is a DNA repair gene that participates in the base excision repair pathway. To date, many studies have been performed to investigate the association between the XRCC1 polymorphisms and risk of cancers such as breast cancer, and gastroesophageal cancer, but the number of studies that focused on glioma is relatively small.

30 Oct 2013

Angiochem initiates ANG1005 Phase 2 study in patients with recurrent high-grade glioma

Angiochem, a clinical stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier (BBB), today announced the initiation of a Phase 2 clinical study with ANG1005, a novel paclitaxel-peptide drug conjugate, in patients with recurrent high-grade glioma.

22 Oct 2013

immatics biotechnologies closes €34 million Series D financing round

immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company developing advanced multi-peptide cancer vaccines that are active against cancer, today announced that it has closed a €34 million Series D financing round.

15 Oct 2013

Researchers discover drug that halts growth of brain tumor cells

Working with mice, Johns Hopkins researchers have discovered that weeks of treatment with a repurposed FDA-approved drug halted the growth of - and ultimately left no detectable trace of - brain tumor cells taken from adult human patients.

24 Sep 2013

Nanodiamonds deliver chemotherapy directly into brain tumors

Researchers at UCLA's Jonsson Comprehensive Cancer Center have developed an innovative drug-delivery system in which tiny particles called nanodiamonds are used to carry chemotherapy drugs directly into brain tumors.

13 Sep 2013

Umbilical cord mesenchymal stem cells may have targeting capacity for glioma

Glioblastoma is the most common ma-lignant primary brain tumor in adults. The aggressive growth manner, characterized by marked angiogenesis and extensive tumor cell invasion into normal brain parenchyma with frequent formation of tumor microsatellites at distal sites, makes eradication impossible even after extensive microsurgical resection combined with current standard chemoradiation and adjuvant temozolomide.

11 Sep 2013

New drug delivery system using NDs allows for direct application of chemotherapy to brain tumors

Researchers at UCLA's Jonsson Comprehensive Cancer Center have developed a new drug delivery system using nanodiamonds (NDs) that allows for direct application of chemotherapy to brain tumors with fewer harmful side effects and better cancer-killing efficiency than existing treatments.

10 Sep 2013